Its secures £8.65m series-a equity funding round extension to fund synthetic flu vaccine study (news-medical-net)

2010-02-17 | Source

Immune Targeting Systems (ITS) Limited (?ITS?), one of the leading developers of synthetic vaccines for mutating viruses, today announced it had secured a Series-A equity funding round extension for £8.65m which brings the total Series A financing to £13.15m. The company?s key investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital ...